RSMDF:OTO-Resmed Inc Ord (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 17.7

Change

0.00 (0.00)%

Market Cap

USD 10.10B

Volume

N/A

Analyst Target

USD 11.49
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

N/A

USD 102.35B
ESLOF EssilorLuxottica Société ano..

N/A

USD 97.51B
HOCPY Hoya Corp

N/A

USD 41.31B
HOCPF HOYA Corporation

N/A

USD 41.31B
CLPBY Coloplast A

N/A

USD 29.16B
CLPBF Coloplast A/S

N/A

USD 26.54B
TRUMY Terumo Corp ADR

N/A

USD 25.10B
TRUMF Terumo Corporation

N/A

USD 24.91B
SAUHF Straumann Holding AG

N/A

USD 24.13B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 22.04B

ETFs Containing RSMDF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.02% 82% B 67% D+
Dividend Return 0.30% 32% F 7% C-
Total Return 9.32% 80% B- 67% D+
Trailing 12 Months  
Capital Gain -18.43% 47% F 45% F
Dividend Return 0.87% 40% F 10% F
Total Return -17.57% 49% F 44% F
Trailing 5 Years  
Capital Gain 80.61% 92% A 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.61% 84% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 15.03% 62% D 62% D
Dividend Return 15.82% 59% D- 59% D-
Total Return 0.79% 37% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 73.12% 35% F 39% F
Risk Adjusted Return 21.64% 62% D 56% F
Market Capitalization 10.10B 90% A- 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.